Summer is a good time to review investment activity for pharmaceutical and biotech companies in the year so far and a new report shows that there’s still life for life science IPOs.
More life science companies went public in the first half of the year than tech companies, and there are more of the former than the latter waiting in the pipeline. But a bigger-picture view of the numbers shows an overall slowing trend for both life science and tech IPOs, and depending on the sector. In fact there are different factors behind the decisions driving these companies to go public.
